Trial
NCT05217667
Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Arrowhead Pharmaceuticals
Collaborators
—
Condition
Homozygous Familial Hypercholesterolemia
Intervention
ARO-ANG 3 Injection
Why stopped
Business decision, unrelated to safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-12